<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186443</url>
  </required_header>
  <id_info>
    <org_study_id>TT-01</org_study_id>
    <nct_id>NCT03186443</nct_id>
  </id_info>
  <brief_title>Pregabalin Treatment and Prevention Post-herpetic Neuralgia</brief_title>
  <official_title>Prevention Effect of Pregabalin on Postherpetic Neuralgia: A Multicenter, Randomized, Double-blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic
      neuralgia still need to confirm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregabalin has been recommended as the first—line drug for post-herpetic neuralgia (PHN)
      therapy currently due to its efficacy and safety. However,there was no valuable report at
      present on the clinical efficacy of pregabalin for acute and subacute herpetic neuralgia
      (SHN), expect for a smaller study which included 29 outpatients who had acute zoster pain for
      a period of 7-1 4 days. And it is not clear whether early application of pregabalin can
      reduce the incidence of PHN.

      Therefore, this study was rational designed to evaluate the efficacy and safety of pregabalin
      in the treatment of herpetic neuralgia，and follow—up to the 8 months, evaluation whether
      impacting the accidence of PHN.

      It is the first time in the international that treating acute herpetic neuralgia (AHN) and
      SHN with pregabalin as a large sample size clinical trial. The results of this study will be
      great significance for guiding the clinical medication.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>control group is to oral gabapentin 0.4 tid； experiment group is to oral pregabalin 300mg q 12h</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the changes of numerical rating scale (NRS)</measure>
    <time_frame>from the date of start to 8 month</time_frame>
    <description>Pain intensity was rated on an 1 1-point numerical rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>baseline and 8th month</time_frame>
    <description>quality of life was rated on Brief Pain Inventory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>Herpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>experiment group: pregabalin 300mg,q12h for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>compared to pregabalin effect on herpetic neuralgia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin was taken 300mg,q 12h for 6 month.</description>
    <arm_group_label>pregabalin</arm_group_label>
    <other_name>pregabalin tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin was taken 0.4, tid for 6 month.</description>
    <arm_group_label>gabapentin</arm_group_label>
    <other_name>gabapentin tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pain occurs within 90 days of rash onset

          2. Numerical rating scale (NRS) greater than 50 mm

        Exclusion Criteria:

          1. Patient with nervous system disorders which impair completing the pain diaries

          2. Patient with history of illicit drug or alcohol abuse within the last 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Wan, Ph.D.,M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital,Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Wan, Ph.D.,M.D.</last_name>
    <phone>18122256632</phone>
    <email>wanli5000cn@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National drug clinical trial fundation</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chu-Yan Lin, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Li Wan, Ph.D.,M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>herpetic neuralgia</keyword>
  <keyword>post-herpetic neuralgia</keyword>
  <keyword>pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

